Novel Liposomal Formulation of OCZ103

Oncozyme is looking to improve its lead oncology product candidate OCZ103 by incorporating it in nanometer-scale lipid particles known as liposomes. Liposomes have already demonstrated their usefulness in transporting anti-cancer drugs and improving the efficacy and safety aspects of drugs. Liposomal formulation development requires a highly skilled individual both technically and theoretically. The intern who will work on this project will put her skills to work in an industrially oriented formulation development project, where theory counts, but where results must be presented and experiments prepared with a pharmaceutical regulatory aspect in mind. The intern will be in touch with the industrial expectations, while the partner will profit from the intern’s know-how guided by its supervisor.

Faculty Supervisor:

Christine Allen

Student:

Partner:

Oncozyme Pharma Inc

Discipline:

Life Sciences

Sector:

Manufacturing

University:

University of Toronto

Program: